NIKKEI 225
33,231.27 -200.24 (-0.60%) HANG SENG
16,646.05 -184.25 (-1.09%) CRUDE OIL
73.29 -0.78 (-1.05%) GOLD FUTURES
2,046.70 -43.00 (-2.06%) DOW
36,213.38 -32.12 (-0.09%) Bitcoin GBP
33,085.26 +1,741.28 (+5.56%)
AstraZeneca PLC (AZN)
| Previous close | 64.79 |
| Open | 64.87 |
| Bid | 65.01 x 1100 |
| Ask | 65.02 x 1300 |
| Day's range | 64.61 - 65.11 |
| 52-week range | 61.73 - 76.56 |
| Volume | |
| Avg. volume | 5,492,947 |
| Market cap | 201.599B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 34.41 |
| EPS (TTM) | 1.89 |
| Earnings date | N/A |
| Forward dividend & yield | 1.45 (2.24%) |
| Ex-dividend date | 10 Aug 2023 |
| 1y target est | 82.69 |
ZacksLilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
ReutersAstraZeneca, AI biologics firm Absci tie up on cancer drug
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
- Reuters
UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drug
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
